|Year : 2022 | Volume
| Issue : 3 | Page : 454-457
Seroprevalence of hepatitis B viral infection in the okpoko community
Ndubuisi Obiora Nwachukwu1, Christopher Uche Okoronkwo2, Precious Ndudi Duru3
1 Department of Microbiology, Abia State University, Uturu, Abia
2 Department of Food Science and Technology, Abia State University, Uturu, Abia
3 Department of Medical Laboratory Sciences, Nnamdi Azikiwe University, Awka, Anambra, Nigeria
|Date of Submission||06-Apr-2022|
|Date of Decision||16-May-2022|
|Date of Acceptance||17-Jun-2022|
|Date of Web Publication||17-Sep-2022|
Ndubuisi Obiora Nwachukwu
Department of Microbiology, Abia State University, P. M. B 2000, Uturu, Abia
Source of Support: None, Conflict of Interest: None
Background: Hepatitis B virus infection (HBV) is a potentially life-threatening liver infection. Little is known about seroprevalence at the community level. A cross-sectional, community-based study was conducted at Okopko, an urban slum in Ogbaru Local Government Area of Anambra State, Nigeria, using a multistage sampling technique. Stages were the constituency level, ward, and household levels. A total of 867 participants were enrolled. Methods: Testing for the markers of HBV was performed using Diagnostic Kit (USA). The test panel detects hepatitis B surface antigen (HBsAg), hepatitis e antigen (HBeAg), antibody to e antigen (HBeAb), core antibody (HBcAb), and surface antibody (HBsAb) using colloidal gold and membrane chromatographic technology. Results: The seroprevalence of HBsAg was 6.6%. Seroprevalence was higher in males (7.4%) than in females (5.5%) (P > 0.05). The peak seroprevalence occurred in the age group of 40–49 years for both males (13.6%) and females (8.1%) (P < 0.05). Exactly 4.7% were positive for HBeAg and 5.8% for HBsAg + HBeAg + HBcAb. Only 1% was positive for HBsAb. Conclusion: Okpoko community has a high intermediate prevalence rate of HBV infection. The HBV vaccination level is very low in the community.
Keywords: Hepatitis B, viral infection, seroprevalence, Nigeria
|How to cite this article:|
Nwachukwu NO, Okoronkwo CU, Duru PN. Seroprevalence of hepatitis B viral infection in the okpoko community. Biomed Biotechnol Res J 2022;6:454-7
|How to cite this URL:|
Nwachukwu NO, Okoronkwo CU, Duru PN. Seroprevalence of hepatitis B viral infection in the okpoko community. Biomed Biotechnol Res J [serial online] 2022 [cited 2022 Oct 3];6:454-7. Available from: https://www.bmbtrj.org/text.asp?2022/6/3/454/356158
| Introduction|| |
Hepatitis B virus (HBV) is one of the causes of viral infections of the liver. Individuals who are chronically infected can transmit the virus to others. Other means of transmission include infected mother to child during birth, through sex with an infected partner, and multi-sex partners. Health workers are also at risk of contracting the virus.,
Worldwide, over two billion people are infected with HBV and about 350 million people are chronic HBV carriers. More than 1 million people die each year from cases related to viral hepatitis. In sub-Saharan Africa, almost 8% of this global burden exists. Hepatitis B viral infection is highly endemic in Nigeria, and had previously been reported in different parts of the country.,,
At the community level in Nigeria, not much is known about HBV infection. However, early detection and treatment is a key to breaking transmission at the community level. The World Health Organization is poised to eliminate HBV as a public health challenge by the year 2030. We, therefore, determined the seroprevalence of HBV in the Okpoko community of Anambra State, Nigeria.
| Methods|| |
A community-based study was carried out at Okpoko, an urban slum in Ogbaru Local Government Area of Anambra State, Nigeria, between February 2018 and February 2019. Okpoko has an estimated population of 670,000. The population density is estimated at 49.78 persons per hectare and is inhabited by poor- and middle-class families.
A multistage sampling was performed at the constituency level, ward (smaller administrative units), and household levels. Multilevel sampling was to generate a representative sample, thus, distributing the overall sample size proportionately to the size of the population. Study participants were drawn from Okpoko 1 constituency, made up of six wards. A total of 867 people participated. Sociodemographic characters of the participants were collated using a structured questionnaire.
Testing for HBV Markers
Venous blood (5 ml) was collected from each participant and used for the investigations.
Diagnostics Kit (USA), which utilizes colloidal gold and membrane chromatography technology, was used for the detection of HBV markers in whole blood. The test panel included the qualitative detection of hepatitis B surface antigen (HBsAg), hepatitis e antigen (HBeAg) in whole blood with dual-antigen sandwich method, and measures HBsAb with dual-antigen sandwich method, and measures HBeAb and HBcAb with neutralization competitive inhibition method. Results were interpreted as positive or negative based on kit manufacturers.
Interpretation of HBV test results
HBV status was defined as follows: HBsAg positive – it indicates that the individual has a current infection, HBeAg positive – the presence of HBV nucleocapsid gene (HBeAg) indicates active viral replication in individuals with high levels of viremia who are likely to transmit the virus, HBeAb positive – the presence of antibodies to HBV nucleocapsid gene (HBeAb) indicates that the individual is recovering from as a result of the immune system response to HBeAg and has a reduced level of infectivity, HBsAb positive is considered evidence of being immune to HBV due to vaccination, and HBcAb is considered evidence of previous exposure.
Ethical approval and patient consent
Approval for the study was obtained from the Health and Ethics Committee of Ogbaru Local Government Area. Approval date/No: Approval was conveyed on May 8, 2018. Approval No.: OGB/HEC/018/0118.
The study was conducted in accordance with the ethical principles mentioned in the Declaration of Helsinski (2013).
Participants voluntarily consented to participate.
Data generated were analyzed using descriptive statistics and categorical variables expressed in percentages. Differences in proportions were compared using Chi-square. Level of significance was set at P < 0.05.
| Results|| |
A total of 867 participants, 485 (55.9%) males and 382 (44.1%) females participated in the study. Exactly 29.3% of the participants were in the age group of 40–49 years old and were 65.2% [Table 1].
|Table 1: Demographic characteristics of participants in the Okpoko community|
Click here to view
The seroprevalence of HBsAg in the community was 6.6%. Males (7.4%) were more infected than females (5.5%) (P > 0.05). The highest prevalence of HBsAg was observed in the 40–49 years old. A similar observation was seen in the females, with a peak of 8.1% in the 40–49 years old. A statistical difference existed between age and being HBsAg positive [Table 2].
|Table 2: Seroprevalence of HBsAg among participants in the Okpoko community|
Click here to view
Forty-one (4.7%) participants were HBeAg positive. Similarly, HBcAb seroprevalence was 6.0%. The proportion of the studied population who were positive for HBsAg + HBeAg + HBcAb was 5.8%. Only 1% of the participants had evidence of protective antibodies (HBsAb) in their serum [Table 3].
|Table 3: Hepatitis B virus biomarkers among participants in the Okpoko community|
Click here to view
| Discussion|| |
Hepatitis B viral infection is a public health problem; with high rates of morbidity and mortality globally. In the Okpoko community, the overall HBsAg seroprevalence was 6.6%. This is similar with 6.0% reported by Moses et al. among healthy urban Nigerians and lower than 12.2% in a National Survey. This result is also in consonant with 6.89% previously reported in China. It shows that HBV infection is endemic in Okpoko.
Males had higher HBsAg seroprevalence than females. This agrees with earlier results. It is, however, contrary to findings where higher prevalence was seen in females., The gender difference is also probably due to the natural protective influence of estrogen against inflammation in women; higher exposure to carcinogens such as tobacco and alcohol in men.
We observed that peak seroprevalence occurred in the age group 40–49 years old. This is in line with previous studies ,, where seroprevalence increased with age for both sexes. Older people in the community are likely to transmit the infection through their lifestyle including sexual promiscuity and marital status. Interventions targeted at this age group will further reduce the burden and break community transmission.
The results of HBV biomarkers revealed that 4.7% of the Okpoko community were HBeAg positive. These indicate active infection and infectivity. The seroprevalence of HBsAg + HBeAg + HBcAb was 5.8%. This represents the acute phase of HBV infection. HBV transmission, therefore, could be ongoing in the community.
Only 1% of the population had evidence of protective antibodies in their sera (HBsAb) as a result of vaccination. The HBV vaccination rate is low. The knowledge and attitude of the populace to immunization generally may have contributed to this low rate.,
Previous exposure to HBV is a risk factor for contracting the infection. This is supported by our findings as 6.0% of the Okpoko community were previously exposed to the virus.
| Conclusion|| |
Okpoko community has a high intermediate prevalence rate (5–7.99%) of HBV infection. Vaccination against HBV is very low.
Limitation of study
We did not carry out HBV DNA studies to ascertain highly infectious carriers. Our findings should be interpreted in the light of the fact only Okpoko 1 constituency was studied. This could compromise the overall HBV prevalence, though Okpoko has the highest population in Ogbaro Local Government Area.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
| References|| |
Salma M, Hashim S, Fatiha L, Abdamagid Z, Abdelonaheb B. A systematic review of the current hepatitis B viral infection and hepatocellular carcinoma situation in Mediterranean countries. BioMed Res Int 2020;2020:7027169.
Yazie TD, Tebeje MG. An updated systematic review and meta-analysis of the prevalence of hepatitis B virus in Ethiopia. BMC Infect Dis 2019;19:917.
Hebo HJ, Gemeda DH, Abdusemed KA. Hepatitis B and C viral infection: Prevalence, knowledge, attitude and practices and occupational exposure among healthcare workers of Jimma University Medical Center, South west Ethiopia. Sci World J 2019;2019:11.
World Health Organization. Global Hepatitis Report. Geneva, Switzerland: World Health Organization; 2017.
Olayinka AT, Oyemakinde A, Balogun MS, Ajudua A, Nguku P, Aderinola M, et al.
Seroprevalence of hepatitis B infection in Nigeria: A National Survey. Am J Trop Med Hyg 2016;95:902-7.
Ginzberg D, Wong RJ, Gish R. Global HBV burden: Guesstimates and facts. Hepatol Int 2018;12:315-29.
Stasi C, Silvestri C, Voller F. Emerging trends in epidemiology of hepatitis B virus infection. J Clin Transl Hepatol 2017;5:272-6.
Abraham VM, Godwin IA, Priscillia UM, Jonathan TK, Solomon OA. Prevalence of HBsAg and antibodies to hepatitis C in the general population of Benue State, Central Nigeria. Am J Trop Med Hyg 2020;102:995-1000.
Omatola CA, Onoja BA, Agama J. Detection of hepatitis B surface antigen among febrile patients in Ankpa, Kogi State, Nigeria. J Trop Med 2020;2020:5136785.
Berinyuy BE, Alawode RA, Mohammed AB, Babalola BS, Mustapha A, Oshevire RM, et al
. Prevalence of hepatitis B virus in Nigeria: Review update. Ann Public Health Epidemiol 2019;1:2019.
Mohammed Y, Sharif A, Dako N. Seroprevalence of HBsAg among patients with febrile illnesses in Murtala Muhammad Specialist Hospital, Kano, Nigeria. Bayero J Pure Appl Sci 2015;8:19-23.
Bhattarai S, Smriti KC, Pradhan PM, Lama S, Rijal S. Hepatitis B vaccination status and needle-stick and sharps-related Injuries among medical school students in Nepal: A cross-sectional study. BMC Res Notes 2014;7:774.
UN-HABITAT. The State of African Cities Report. United Human Settlement Programme. (UN-HABITAT); 2008.
Petruzziello O. Epidemiology of hepatitis B surface antigen (HBsAg) and hepatitis C virus (HCV) related hepatocellular carcinoma. Open Virol J 2018;12:26-38.
World Health Organization. Global Health Sector Strategy on Viral Hepatitis 2016-2021. Geneva, Switzerland: WHO; 2016.
Moses PA, Silas DG, Simon P, Obadiah G. Hepatitis B viral infection in apparently healthy urban Nigerians: Data from pre-vaccination test. J Infect Dev Countr 2010;4:397-400.
Wang H, Men P, Xiao Y, Gao P, Lv M, Yuan Q, et al.
Hepatitis B infection in the general population of China: A systematic review and meta-analysis. BMC Infect Dis 2019;19:811.
Vilibic-Cavlek T, Kucinar J, Ljubin-Sternak S, Kaic B, Lazaric SL, Kolric C. Prevalence of viral hepatitis in Croatia adult population undergoing routine check-up, 2010-2011. Cent Eur J Public Health 2014;22:29-33.
Yamada H, Fujimoto M, Svay S, Lim O, Hok S, Goto N, et al.
Seroprevalence, genotypic distribution and potential risk factors of hepatitis B and C virus infections among adults in Siem Reap, Cambodia. Hepatol Res 2015;45:480-7.
Faruki AE, Azouaoui N, Agodad M, Aghrouch M, Nmili L. Prevalence of HBsAg in pregnant women in Regional Hospital center Hassan Li in Agadir-Morrocco. IOSR J Dent Med Sci 2019;18:69-72.
Min DY, Huang WY, Yang JY. Prevalence of hepatitis B among minority population in Guizhou province. Mod Prev Med 2016;43:11-4.
Bai S, Zhang H, Zhaxi WS. Investigation on the sero-epidemiology of hepatitis B virus in Tibetan peasant and herdsmen of Gamba County. Chin Hepatol 2017;22:314-6.
Elduma AH, Elgabar HE. Coinfection of hepatitis B and C in patients infected with HIV in Sudan. Am J Res Commun 2015;3:88-96.
Spearman CW, Afihene M, Ally R, Apica B, Awuku Y, Cunha L, et al.
Hepatitis B in sub-Saharan Africa: Strategies to achieve the 2030 elimination targets. Lancet Gastroenterol Hepatol 2017;2:900-9.
Xia W, Dia DF, Sing LX. Prevalence of hepatitis B surface antigen and antibodies to HBsAg among 1-59 year olds, Hunan Province. Chin J Vaccin Immun 2015;21:11-4.
Samsunder N, Ngcapu S, Lewis L, Baxter C, Cawood C, Khanyile D, et al.
Seroprevalence of hepatitis B virus: Findings from a population-based household survey in KwaZulu-Natal, South Africa. Int J Infect Dis 2019;85:150-7.
Sadoh AE, Sahol WE. Serological markers of hepatitis B infections in infants presenting for their immunization. Niger J Paed 2013;40:248-53.
Tang L, Kottilil S, Wilson E. Strategies to eliminate HBV infection: An update. Future Viol 2020;15:35-41.
Isamail SA, Cuadros DF, Benova L. Hepatitis B in Egypt: A cross-sectional analtsis of prevalence and risk factors for active infection from a national survey. Liver Int 2017;37:1814-22.
[Table 1], [Table 2], [Table 3]